M
Morris Sherman
Researcher at University Health Network
Publications - 163
Citations - 16050
Morris Sherman is an academic researcher from University Health Network. The author has contributed to research in topics: Hepatocellular carcinoma & Hepatitis C. The author has an hindex of 46, co-authored 163 publications receiving 14849 citations. Previous affiliations of Morris Sherman include University of Toronto & Toronto General Hospital.
Papers
More filters
Journal ArticleDOI
Management of hepatocellular carcinoma.
Jordi Bruix,Morris Sherman +1 more
TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.
TL;DR: Studies now aim to identify molecular markers and imaging techniques that can detect patients with HCC at earlier stages and better predict their survival time and response to treatment.
Journal ArticleDOI
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Jordi Bruix,Jean-Luc Raoul,Morris Sherman,Vincenzo Mazzaferro,Luigi Bolondi,Antonio Craxì,Peter R. Galle,Armando Santoro,Michel Beaugrand,Angelo Sangiovanni,Camillo Porta,Guido Gerken,Jorge A. Marrero,Andrea Nadel,Michael Shan,M. Moscovici,D. Voliotis,Josep M. Llovet +17 more
TL;DR: The SHARP trial as discussed by the authors showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage and prior therapy.
Journal ArticleDOI
Sequential Phase I and II Trials of Stereotactic Body Radiotherapy for Locally Advanced Hepatocellular Carcinoma
Alexis Bujold,Christine Massey,John Kim,James D. Brierley,Charles Cho,Rebecca Wong,Rob Dinniwell,Zahra Kassam,Jolie Ringash,Bernard Cummings,Jenna Sykes,Morris Sherman,Jennifer J. Knox,Laura A. Dawson +13 more
TL;DR: Results of prospective trials of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma with strong rationale for studying SBRT for HCC in a randomized trial are described.
Journal ArticleDOI
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Regina V. Tse,Maria A. Hawkins,Gina Lockwood,John Kim,Bernard Cummings,Jennifer J. Knox,Morris Sherman,Laura A. Dawson +7 more
TL;DR: Individualized six-fraction SBRT is a safe treatment for unresectable HCC and IHC and no radiation-induced liver disease or treatment-related grade 4/5 toxicity was seen within 3 months after S BRT.